Abbisko Cayman Limited

2256

KYG0028A1085

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 08:08:04 06/02/2026 GMT			5-day change	1st Jan Change
12.64 ^HKD	-1.63%		+1.12%	-2.84%

01-13	Abbisko Cayman's new drug application for pimicotinib formally accepted by U.S. FDA	RE
01-13	Abbisko Tumor Treatment Pimicotinib Accepted for U.S. Review	MT

Abbisko Tumor Treatment Pimicotinib Accepted for U.S. Review

Published on 01/13/2026 at 04:48 am GMT

MT Newswires

Latest news about Abbisko Cayman Limited

01-13	Abbisko Cayman's new drug application for pimicotinib formally accepted by U.S. FDA	RE
01-13	Abbisko Tumor Treatment Pimicotinib Accepted for U.S. Review	MT
01-13	Abbisko Therapeutics Announces FDA Acceptance of the Nda for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor	CI
12-24	Abbisko Unit Gets China Investigational New Drug Clearance for Tumor Drug	MT
12-24	Abbisko Cayman says NMPA clears IND application for unit's Abbisko's Absk141	RE
12-22	Abbisko Unit Gets China Nod for Tenosynovial Giant Cell Tumor	MT
12-22	Abbisko Cayman says Abbisko Therapeutics' CSF-1R inhibitor Pimicotinib approved by China NMPA	RE
12-16	Abbisko Unit Begins Phase 2 Dosing of ABSK061 for Achondroplasia	MT
12-02	Abbisko's IND Application for Cancer Therapy Cleared by U.S. FDA	MT
12-01	Abbisko Cayman says U.S. FDA clears IND application for ABSK141	RE
11-03	Abbisko Unit Doses First Patient in Lung Cancer Study	MT
15/09/25	Tranche Update on Abbisko Cayman Limited's Equity Buyback Plan announced on March 3, 2025.	CI
28/08/25	Abbisko Cayman subscribes $10 mln in callable zero coupon notes	RE
21/08/25	Abbisko Units Gets China Clearance for Lung Cancer Drug Application; Shares Jump 3%	MT
20/08/25	Abbisko Cayman says CDE of NMPA clears IND for Abbisko's PD-L1 inhibitor combo for NSCLC	RE
05/08/25	Abbisko's H1 Profit, Revenue Rise	MT
04/08/25	Abbisko Cayman Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
04/08/25	Abbisko Cayman posts H1 revenue RMB 657.1 million	RE
04/08/25	Tranche Update on Abbisko Cayman Limited's Equity Buyback Plan announced on June 18, 2024.	CI
23/07/25	Abbisko Unit Doses First Patient in Phase 1 Trial of ABSK131	MT
23/06/25	Abbisko Therapeutics Co., Ltd. Completes First Patient Enrollment of Observational Study for the Treatment of Achondroplasia	CI
23/06/25	Abbisko Begins Observational Study Enrollment for Achondroplasia Drug	MT
20/06/25	Abbisko Cayman Limited announces an Equity Buyback for HKD 200 million of its issued share capital.	CI
17/06/25	Abbisko Cayman Limited's Equity Buyback announced on June 18, 2024, has expired with 16,006,000 shares, representing 2.52% for HKD 93.28 million.	CI
16/06/25	Abbisko Cayman Doses First Patient in Registrational Study of Liver Cancer Drug	MT

Abbisko Cayman Ltd is a China-based clinical-stage biopharmaceutical company. The Company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Companyâ€™s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Employees

226

Sector

Biotechnology & Medical Research

Calendar

03-11 - Q4 2025 Earnings Release (Projected)

More about the company